SciSparc Signs Agreement to Conduct its Clinical Trial in Autism Spectrum Disorder with Soroka Medical Center
TEL AVIV, Israel, Jan. 09, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced it has signed an agreement with the Soroka University Medical Center, in Be'er-Sheva, Israel ("Soroka Medical Center") to conduct the Company’s clinical study for SCI-210 in patients suffering from autism spectrum disorder ("ASD").
- During 2022, the Company received approvals from the Israeli Ministry of Health as well as the Ethics Committee of the Soroka University Medical Center, in Be'er-Sheva, Israel, to conduct the Company’s clinical trial.
- “The signing of the agreement with Soroka Medical Center represents another step towards commencing our clinical trial in ASD,” commented Oz Adler, SciSparc's Chief Executive Officer.
- Soroka Medical Center is yet another example for our continuous efforts to collaborate with leading medical institutions in the world."
- The term "spectrum" in autism spectrum disorder refers to the wide range of symptoms and severity.